Case Report: Durable complete response to olaparib in a patient with BRCA2-driven metastatic gastric adenocarcinoma after failure of chemo-immunotherapy.
증례보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: advanced gastric cancer
I · Intervention 중재 / 시술
gastrectomy with intraoperatively detected liver metastases
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The patient achieved a complete metabolic response on FDG PET-CT, which has been sustained for more than three years under continuous olaparib therapy with acceptable tolerability. This case highlights the importance of molecularly guided treatment strategies and homologous recombination repair deficiency in selected patients with advanced gastric cancer.
Metastatic gastric adenocarcinoma is associated with poor prognosis and limited treatment options after failure of chemotherapy and immunotherapy.
APA
Karakaya G (2026). Case Report: Durable complete response to olaparib in a patient with BRCA2-driven metastatic gastric adenocarcinoma after failure of chemo-immunotherapy.. Frontiers in oncology, 16, 1769043. https://doi.org/10.3389/fonc.2026.1769043
MLA
Karakaya G. "Case Report: Durable complete response to olaparib in a patient with BRCA2-driven metastatic gastric adenocarcinoma after failure of chemo-immunotherapy.." Frontiers in oncology, vol. 16, 2026, pp. 1769043.
PMID
42022316 ↗
Abstract 한글 요약
Metastatic gastric adenocarcinoma is associated with poor prognosis and limited treatment options after failure of chemotherapy and immunotherapy. Although BRCA1/2 alterations are well-established predictive biomarkers for PARP inhibitor efficacy in several malignancies, their role in gastric cancer remains incompletely defined. We report a 65-year-old male with metastatic gastric adenocarcinoma who underwent gastrectomy with intraoperatively detected liver metastases. The disease progressed following platinum-based chemotherapy combined with nivolumab and subsequent paclitaxel-ramucirumab therapy. Comprehensive genomic profiling using the Tempus xT assay identified a pathogenic germline BRCA2 frameshift mutation with somatic loss of heterozygosity. Based on this molecular profile, off-label olaparib therapy was initiated. The patient achieved a complete metabolic response on FDG PET-CT, which has been sustained for more than three years under continuous olaparib therapy with acceptable tolerability. This case highlights the importance of molecularly guided treatment strategies and homologous recombination repair deficiency in selected patients with advanced gastric cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- From mutation to treatment: The dual role of BRCA1 and BRCA2 in gynecological malignancy development and management a systematic review.
- Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know?
- Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation.
- PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer.
- Augmented myeloablative conditioning with olaparib in allogeneic hematopoietic stem cell transplantation for relapsed/refractory RUNX1::RUNX1T1-positive acute myeloid leukemia.
- Targeting RNase H2: A dual-mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in TNBC.